APG-1387 + paclitaxel + carboplatin

**APG-1387 + paclitaxel + carboplatin** is an experimental combination therapy for cancer comprised of three agents: \n- **APG-1387** is a bivalent SMAC (Second Mitochondria-derived Activator of Caspase) mimetic that targets and inhibits inhibitor of apoptosis proteins (IAPs) such as cIAP1, cIAP2, and XIAP, promoting cancer cell death through apoptosis and sensitizing tumor cells to immune-mediated and cytotoxic therapy[1][2]. \n- **Paclitaxel** is a microtubule inhibitor that blocks cell cycle progression and induces cell death. \n- **Carboplatin** is a platinum-based chemotherapeutic that induces DNA damage and apoptosis. \nThis combination is investigated for synergistic anti-tumor effects, particularly in solid tumors like hepatocellular carcinoma and ovarian cancer, leveraging APG-1387's ability to sensitize cells to apoptosis and augment the effects of classic cytotoxic agents. APG-1387 is under clinical investigation, primarily developed by Ascentage Pharma[2][3].